日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Structural basis of OsCERK1-mediated signal activation and transduction in rice immunity and symbiosis.

水稻免疫和共生中 OsCERK1 介导的信号激活和转导的结构基础。

Su Zihui, Zhou Sicong, Yu Shiting, Ning Xuan, Fu Qiong, Fu Qiang, Zhao Qiaoqiao, Ma Jinxue, Niu Chengqun, Kong Yanqiong, Peng Yujun, Ming Zhenhua

Mechanistic Insights Into Immune Cell Dysregulation Mediated by Novel Heterozygous Variants in CARD11 and MALT1.

CARD11 和 MALT1 中新型杂合变异介导的免疫细胞失调的机制见解。

Li Rui, Sun Xiaochen, Bao Wei, Yu Haolan, Dan YuQing, Wu Chunmei, Ma Yan, Yin Hanlin, Lin Wanyi, Lu Liangjing, Fu Qiong, Yang Chenghua

Effectiveness and safety of tofacitinib versus calcineurin inhibitor in interstitial lung disease secondary to anti-MDA5-positive dermatomyositis: a multicentre cohort study

托法替尼与钙调磷酸酶抑制剂治疗抗MDA5阳性皮肌炎继发间质性肺病的疗效和安全性:一项多中心队列研究

Wu, Wanlong; Guo, Bingpeng; Sun, Wenjia; Chen, Dan; Xu, Wenwen; Chen, Zhiwei; Fu, Yakai; Ye, Yan; Lyu, Xia; Xue, Zhixin; Wang, Kaiwen; Zhao, Jiangfeng; Xie, Cuiying; Chen, Yi; Ye, Chunhua; Dai, Min; Fan, Wei; Li, Jia; Wang, Xiaodong; Xue, Yu; Wan, Weiguo; Sun, Li; Wu, Huaxiang; Luo, Qun; Han, Qian; Fu, Qiong; Ye, Shuang

CAR-based cell therapies for systemic lupus erythematosus

基于 CAR 的细胞疗法治疗系统性红斑狼疮

Wang, Yiyang; Lu, Liangjing; Ye, Shuang; Fu, Qiong

Efficacy and safety of ruxolitinib in adult patients with refractory rheumatic disease-associated macrophage activation syndrome

鲁索替尼治疗难治性风湿病相关巨噬细胞活化综合征成人患者的疗效和安全性

Li, Jingjing; Wang, Ran; Chen, Jie; Xu, Antao; Fu, Yakai; Lin, Yanwei; Wang, Xiaodong; Ye, Shuang; Yuan, Ye; Du, Fang; Fu, Qiong

Follicular helper T cells (Tfh): heterogeneity in spatial distribution and phenotypic characteristics

滤泡辅助性T细胞(Tfh):空间分布和表型特征的异质性

Shen, Caifeng; Fu, Qiong

Correction: Obinutuzumab in systemic lupus erythematosus: a real-world experience

更正:奥妥珠单抗治疗系统性红斑狼疮:真实世界经验

Wu, Chunmei; Wang, Yinglu; Chen, Shenshen; Lin, Yanwei; Du, Fang; Wang, Xiaodong; Chen, Sheng; Lu, Liangjing; Ye, Shuang; Ding, Huihua; Fu, Qiong

Low-dose emapalumab treatment in refractory macrophage activation syndrome secondary to adult onset still's disease/systemic lupus erythematosus: insights from nine cases

低剂量emapalumab治疗成人斯蒂尔病/系统性红斑狼疮继发的难治性巨噬细胞活化综合征:来自9例病例的启示

Chen, Jie; Zhao, Liling; Lin, Yanwei; Lian, Xinyue; Wang, Haiting; Gu, Liyang; Wang, Ran; Wang, Xiaodong; Ye, Shuang; Fu, Qiong

Obinutuzumab in systemic lupus erythematosus: a real-world experience

奥妥珠单抗治疗系统性红斑狼疮:真实世界经验

Wu, Chunmei; Wang, Yinglu; Chen, Shenshen; Lin, Yanwei; Du, Fang; Wang, Xiaodong; Chen, Sheng; Lu, Liangjing; Ye, Shuang; Ding, Huihua; Fu, Qiong

Rituximab as the first-line treatment in newly diagnosed systemic lupus erythematosus

利妥昔单抗作为新诊断系统性红斑狼疮的一线治疗

Wang, Haiting; Zhao, Liling; Yang, Shaoying; Ding, Huihua; Wu, Wanlong; Yu, Liqin; Jin, Jiajia; Shen, Nan; Fu, Qiong; Ye, Shuang